175 related articles for article (PubMed ID: 35769818)
21. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch.
Hébrant A; Dom G; Dewaele M; Andry G; Trésallet C; Leteurtre E; Dumont JE; Maenhaut C
PLoS One; 2012; 7(10):e37807. PubMed ID: 23115614
[TBL] [Abstract][Full Text] [Related]
22. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
[TBL] [Abstract][Full Text] [Related]
23. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
24. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
25. [Study on the effect and mechanisms of SIGLEC-15 on laryngeal squamous cell carcinoma].
Li SH; Sun J; Chen W
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Jun; 57(6):724-731. PubMed ID: 35725316
[No Abstract] [Full Text] [Related]
26. Long noncoding RNA landscapes specific to benign and malignant thyroid neoplasms of distinct histological subtypes.
Yakushina VD; Strelnikov VV; Tanas AS; Lavrov AV
Sci Rep; 2021 Aug; 11(1):16728. PubMed ID: 34408227
[TBL] [Abstract][Full Text] [Related]
27. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
28. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
29. Unveiling a novel biomarker panel for diagnosis and classification of well-differentiated thyroid carcinomas.
Paricharttanakul NM; Saharat K; Chokchaichamnankit D; Punyarit P; Srisomsap C; Svasti J
Oncol Rep; 2016 Apr; 35(4):2286-96. PubMed ID: 26782318
[TBL] [Abstract][Full Text] [Related]
30. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
31. Genomic amplification of long noncoding RNA HOTAIRM1 drives anaplastic thyroid cancer progression via repressing miR-144 biogenesis.
Zhang L; Zhang J; Li S; Zhang Y; Liu Y; Dong J; Zhao W; Yu B; Wang H; Liu J
RNA Biol; 2021 Apr; 18(4):547-562. PubMed ID: 32951513
[TBL] [Abstract][Full Text] [Related]
32. RNF150 suppresses papillary thyroid carcinoma with ASK1 ubiquitination presenting a direct target via inactivating p38 signaling axis.
Deng W; Wu J; Zheng W; Wang Q; Li D; Kuang H
Cell Biol Int; 2023 Jul; 47(7):1198-1208. PubMed ID: 36950779
[TBL] [Abstract][Full Text] [Related]
33. Factors related to mortality in patients with papillary and follicular thyroid cancer in long-term follow-up.
de Melo TG; Zantut-Wittmann DE; Ficher E; da Assumpção LV
J Endocrinol Invest; 2014 Dec; 37(12):1195-200. PubMed ID: 25037473
[TBL] [Abstract][Full Text] [Related]
34. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
35. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment.
Pan Z; Xu T; Bao L; Hu X; Jin T; Chen J; Chen J; Qian Y; Lu X; Li L; Zheng G; Zhang Y; Zou X; Song F; Zheng C; Jiang L; Wang J; Tan Z; Huang P; Ge M
Mol Cancer; 2022 Oct; 21(1):190. PubMed ID: 36192735
[TBL] [Abstract][Full Text] [Related]
36. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
37. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
38. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
39. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.
Weinberger P; Ponny SR; Xu H; Bai S; Smallridge R; Copland J; Sharma A
Thyroid; 2017 Feb; 27(2):236-252. PubMed ID: 27796151
[TBL] [Abstract][Full Text] [Related]
40. The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.
Pan Z; Li L; Qian Y; Ge X; Hu X; Zhang Y; Ge M; Huang P
Cancer Biol Ther; 2020 Sep; 21(9):853-862. PubMed ID: 32887540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]